title: [Phase II clinical study of recombinant human erythropoietin on the anemia associated with multiple myeloma].
abstract: Safety and efficacy of recombinant human erythropoietin (epoetin alpha) were investigated in anemic patients with multiple myeloma whose hemoglobin (Hb) concentration was less than 10g/dl. Epoetin alpha (3,000IU/body) was given subcutaneously daily for two weeks and the dosage was increased to 6,000IU, 12,000IU and 24,000IU every two weeks when the increment of Hb was insufficient. Cases in which Hb concentration increased by more than 1g/dl or in which blood transfusion requirements decreased by more than 50% were judged to be effective. The overall rate of efficacy was 52.6% (10/19). Response to epoetin alpha treatment was better in patients whose blood erythropoietin level was relatively low. The majority of patients responded to the treatment with up to 6,000IU/body/day but a dosage of more than 12,000IU/body/day was required in some cases. No serious adverse effects or abnormal laboratory findings were observed. These results suggest that high-dose subcutaneous epoetin alpha treatment is effective for anemia associated with multiple myeloma in terms of increasing Hb concentration and reducing blood transfusion.
authors.affiliation: Division of Hematology, Kanto Teishin Hospital.
authors.forename: A
authors.initials: A
authors.lastname: Urabe
authors.forename: H
authors.initials: H
authors.lastname: Mizoguchi
authors.forename: F
authors.initials: F
authors.lastname: Takaku
authors.forename: T
authors.initials: T
authors.lastname: Miyazaki
authors.forename: A
authors.initials: A
authors.lastname: Yachi
authors.forename: Y
authors.initials: Y
authors.lastname: Niitsu
authors.forename: Y
authors.initials: Y
authors.lastname: Miura
authors.forename: Y
authors.initials: Y
authors.lastname: Mutoh
authors.forename: S
authors.initials: S
authors.lastname: Fujioka
authors.forename: T
authors.initials: T
authors.lastname: Nomura
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications*; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin